Skip to Main Content

Paper Details

CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Br J Cancer
16
2020
ABCB1, ALK, CD30, CD30-positive, ALK-rearranged malignancies, Epithelioid inflammatory myofibroblastic sarcoma, Malignant ascites, RANBP2, RANBP2-ALK-rearranged epithelioid, brentuximab-vedotin, ceritinib, crizotinib, eIMS, patient, patients, tariquidar, tumour, tumours, xenograft models, xenografts
Author NameAffiliation
Glenn M MarshallChildren's Cancer Institute, Lowy Cancer Research Centre
Glenn M MarshallKids Cancer Centre, Sydney Children's Hospital
Glenn M Marshall
Jamie I FletcherChildren's Cancer Institute, Lowy Cancer Research Centre
Jamie I Fletcher
  • 1 - 5

Datasets

Release 1.2